Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany

Autor: Griesinger, Frank, Pérol, Maurice, Girard, Nicolas, Durand-Zaleski, Isabelle S., Zacharias, Stefan, Bosquet, Lise, Jänicke, Martina, Quantin, Xavier, Groth, Annika, Fleitz, Annette, Calleja, Alan, Patel, Sonya, Lacoin, Laure, Daumont, Melinda Manley, Penrod, John R., Carroll, Robert, Waldenberger, Daniela, Reynaud, Dorothée, Thomas, Michael J., Chouaid, Christos
Přispěvatelé: University of Oldenburg, Centre Léon Bérard [Lyon], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Curie [Paris], Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Equipe 5 : METHODS - Méthodes de l’évaluation thérapeutique des maladies chroniques (CRESS - U1153), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), UNICANCER, Institut du Cancer de Montpellier (ICM), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), German Center for Lung Research, Centre Hospitalier Intercommunal de Créteil (CHIC), Amgen, Bristol-Myers Squibb, BMS, Eli Lilly and Company, Pfizer, AstraZeneca, Novartis, Roche, Celgene, AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical Company, TPC, Merck Sharp and Dohme, MSD, Cilag, LATITUDE (AXON Communications) provided medical writing services on behalf of the authors and Bristol Myers Squibb Pharmaceuticals Ltd. The authors thank the centres involved in the ESME-AMLC programme for providing the data and each ESME local coordinator for managing the project at the local level. Moreover, the authors also thank the central coordination team of Unicancer and the ESME-AMLC Scientific Committee members for their ongoing support. The authors thank all patients, physicians and study teams participating in the CRISP registry, and the CRISP Executive Committee for their medical leadership., CRISP is an AIO study (no. AIO-TRK-0315) conducted by AIO-Studien-gGmbH (sponsor) in cooperation with iOMEDICO (conception, project management and analysis) and supported by grants from Amgen Ltd., AstraZeneca GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Bristol Myers Squibb GmbH & Co. KGaA, Celgene GmbH, Janssen-Cilag GmbH, Lilly Deutschland GmbH, Merck Sharp & Dohme GmbH, Novartis Pharma GmbH, Pfizer Pharma GmbH, Roche Pharma AG, and Takeda Pharma Vertriebs GmbH & Co. KG., Michael Thomas reports honoraria for scientific meetings from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Daichi Sankyo, GlaxoSmithKline, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi and Takeda, travel support from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Lilly, MSD, Novartis, Pfizer, Roche and Takeda, honoraria for advisory boards from AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and Takeda, and institutional research grants from AstraZeneca, Bristol Myers Squibb, Roche and Takeda., The ESME-AMLC database received financial support from an industrial consortium (AstraZeneca, Merck Sharp & Dohme, Bristol Myers Squibb, Amgen and Roche). Unicancer manages the ESME database (i.e. data collection and analysis) independently., Christos Chouaid reports grants, personal fees and non-financial support from Amgen, AstraZeneca, Aventis, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, GlaxoSmithKline, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi and Takeda outside the submitted work., Annika Groth reports grants from Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Takeda to her employer AIO-Studien-gGmbH., HAL UVSQ, Équipe
Rok vydání: 2022
Předmět:
Zdroj: Lung Cancer
Lung Cancer, 2022, 172, pp.65-74. ⟨10.1016/j.lungcan.2022.08.001⟩
ISSN: 0169-5002
Popis: International audience; Objectives: To describe the impact of immune checkpoint inhibitors (ICIs) on treatment patterns and survival outcomes in patients with locally advanced or metastatic non-small cell lung cancer (aNSCLC) in France and Germany. Materials and Methods: Patients with aNSCLC without known ALK or EGFR mutations receiving first-line (1L) therapy were included from (i) the retrospective Epidemiological-Strategy and Medical Economics Advanced and Metastatic Lung Cancer cohort (ESME-AMLC, France; 2015–2018) and (ii) the prospective Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients platform (CRISP, Germany; 2016–2018). Analyses were stratified according to histology. Survival outcomes were estimated using Kaplan–Meier methodology and stratified by year of 1L therapy. Data sources were analysed separately. Results: In ESME-AMLC and CRISP, 8,046 and 2,359 patients were included in the study, respectively. In both countries, approximately 20 % of all patients received pembrolizumab monotherapy as 1L treatment in 2018. In ESME-AMLC, the proportion receiving an ICI over the course of treatment (any line) increased from 42.2 % (2015) to 56.1 % (2018) in patients with squamous histology, and 28.9 % to 51.9 % with non-squamous/other; in CRISP, it increased from 50.6 % (2016) to 65.2 % (2018) with squamous histology, and 40.8 % to 62.7 % with non-squamous/other. Two-year overall survival from 1L initiation was 36.8 % and 25.6 % in the squamous cohorts and 36.5 % and 30.8 % in the non-squamous/other cohorts in ESME-AMLC and CRISP, respectively. No significant change in overall survival was observed over time; however, the follow-up time available was limited in the later years of the analysis. Conclusion: The results of this joint research from two large clinical databases in France and Germany demonstrate the growing use of ICIs in the management of aNSCLC. Future analyses will allow for the evaluation of the impact of ICIs on long-term survival of patients with aNSCLC.
Databáze: OpenAIRE
Externí odkaz: